Bioquímica y Biología Molecular
Departamento
Jesús
Egido de los Ríos
Publicaciones en las que colabora con Jesús Egido de los Ríos (16)
2014
-
Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice
Journal of Cellular and Molecular Medicine, Vol. 18, Núm. 4, pp. 721-734
2013
-
Proteomic analysis of intraluminal thrombus highlights complement activation in human abdominal aortic aneurysms
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 8, pp. 2013-2020
-
Unraveling biomarkers of abdominal aortic aneurisms by iTRAQ analysis of depleted plasma
Methods in Molecular Biology, Vol. 1000, pp. 157-166
2012
-
Metabolomic study of plasma of patients with abdominal aortic aneurysm
Analytical and Bioanalytical Chemistry, Vol. 403, Núm. 6, pp. 1651-1660
-
Plasma profiling by a protein array approach identifies IGFBP-1 as a novel biomarker of abdominal aortic aneurysm
Atherosclerosis, Vol. 221, Núm. 2, pp. 544-550
2011
-
Animal models of cardiovascular diseases
Journal of Biomedicine and Biotechnology, Vol. 2011
2009
-
Leukotriene B4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis
Cardiovascular Research, Vol. 81, Núm. 1, pp. 216-225
2008
-
Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.
American Journal of Cardiology, Vol. 102, Núm. 1, pp. 12-18
2007
-
Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis
Journal of Pharmacology and Experimental Therapeutics, Vol. 320, Núm. 1, pp. 108-116
2006
-
Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization
Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69
-
El tratamiento con dosis altas de atorvastatina disminuye la inflamación en la aterosclerosis carotídea humana
Clínica e investigación en arteriosclerosis, Vol. 18, Núm. 1, pp. 18-23
-
Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB
Atherosclerosis, Vol. 187, Núm. 1, pp. 139-149
2005
-
HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells
Journal of Cardiovascular Pharmacology, Vol. 45, Núm. 5, pp. 468-475
-
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month
Stroke, Vol. 36, Núm. 8, pp. 1796-1800
2004
2002
-
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells
Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58